meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors target tumor genomic instability and specific DNA damage repair defects. They are approved for treating various tumors, especially those with homologous recombination repair (HRR) deficiencies, such as brca1 gene mutant, brca2 gene mutant and other related genes like Partner and localizer of BRCA2 (PALB2) and RAD51 homolog C (S. cerevisiae) (RAD51C). PARPs (Poly(ADP-Ribose) Polymerases) inhibitors are safe and effective.
Mitri et al.…
References (Sources)
- An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor
- Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
- Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
- Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy
- Parp Inhibitors for the Treatment of Ovarian Cancer
- Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysisMeta-Analysis
- Strategies for the prevention or reversal of PARP inhibitor resistance